Compugen has hired Noam Shani as vice president of biology research and development, where he will oversee the Israeli company’s drug research and development, and manage therapeutic protein candidate discovery, selection, validation, and preclinical and clinical development. Shani joins Compugen from Medgenics, where he was vice president of research and development. He holds a doctoral degree in biology from the Weizmann Institute of Science, in Israel, and completed a postdoctoral fellowship at Johns Hopkins University’s School of Medicine, in Maryland.
PointOne Systems, a bioinformatics company integrating molecular and clinical data, has tapped Frank Langley to serve as president and CEO. Langley most recently served as president and CEO of Pel-Freez Clinical Systems. He succeeds Drew Palin, who led the company for three years. Palin will consult with PointOne during the leadership transition, the company said.
Cisbio announced that Mark Schmeizl has been named national sales director of Cisbio’s US division. Prior to joining Cisbio, Schmeizl served as Northeast district sales manager at Affymetrix. Before that, he spent eight years at the Packard Instrument Company, where he held several senior-level marketing and sales positions, including marketing manager and senior product manager within the company’s Microplate Detection Systems division.
Douglas Williams has resigned his post as chief scientific officer and executive vice president of research and development at Seattle Genetics. According to the Bothell, Wash.-based firm, Williams has stepped down to accept a position with another undisclosed company.
Adrian Butash was named executive vice president and chief marketing officer of Applied DNA Sciences. Butash formerly served as a marketing executive with Celanese and Hoechst Fibers. He also ran his own marketing/advertising agency in New York called Adrian. Los Angeles-based Applied DNA Sciences makes a bio-digital microchip that is used for security and anti-counterfeit applications.